ROVAMYCINE, 1.5 million IU, coated tablets
ROVAMYCINE, 3 million IU, coated tablets
Spiramycin
Rovamycine is available in the form of coated tablets and contains the active substance spiramycin.
Spiramycin is an antibiotic belonging to the macrolide group.
Before starting treatment with Rovamycine, discuss it with your doctor.
If the patient experiences symptoms of an allergy while taking Rovamycine, the medicine should be discontinued
and the doctor should be contacted immediately.
If the patient is allergic to other macrolide antibiotics, they should take Rovamycine with caution and, in case of worrying symptoms, consult a doctor.
If diarrhea occurs during treatment, the doctor should be contacted immediately
and medications that inhibit intestinal peristalsis should not be taken. There have been cases of pseudomembranous colitis after the use of broad-spectrum antibiotics, so it is important to consider this possibility in patients who have developed acute diarrhea during or after antibiotic treatment.
Spiramycin is excreted in small amounts in the urine, and in renal failure, there is no need to modify the dose of the medicine.
It should be used with caution in patients with liver failure due to the possibility of increased side effects.
It is not recommended to use spiramycin in patients with a deficiency of glucose-6-phosphate dehydrogenase activity, as acute hemolysis has been observed in rare cases after the use of spiramycin in this group of patients.
QT interval prolongation
During treatment with macrolide antibiotics, including spiramycin, cases of QT interval prolongation have been observed. Therefore, caution should be exercised when using spiramycin in patients with conditions that favor QT interval prolongation, i.e., patients with:
Severe skin reactions
During treatment with Rovamycine, cases of severe skin reactions have been reported, such as Stevens-Johnson syndrome, toxic epidermal necrolysis, and acute generalized exanthematous pustulosis (AGEP).
Patients will be informed about the symptoms and will be closely monitored for skin reactions. If symptoms of Stevens-Johnson syndrome, toxic epidermal necrolysis (e.g., progressive rash, often with blisters or mucosal lesions), or acute generalized exanthematous pustulosis occur, the use of Rovamycine should be discontinued.
Tablet administration is not recommended in children under 6 years of age (risk of choking).
Tell your doctor about all medicines you are currently taking or have recently taken, as well as any medicines you plan to take.
This is especially important when taking spiramycin with medications containing levodopa and carbidopa - a dose adjustment of levodopa may be necessary.
Medications that prolong the QT interval
Spiramycin, like other macrolide antibiotics, should be used with caution in patients concomitantly receiving medications that prolong the QT interval (e.g., antiarrhythmic medications belonging to class IA and class III, tricyclic antidepressants, certain medications used to treat infections, antipsychotic medications).
Hydroxychloroquine or chloroquine (medications used to treat rheumatoid arthritis, to treat and prevent malaria)
Concomitant use of hydroxychloroquine or chloroquine with Rovamycine may increase the risk of side effects that affect heart function, which can be life-threatening.
The medicine can be taken with or without food.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to have a child, consult your doctor before taking this medicine.
The medicine should only be used in pregnant women if absolutely necessary.
If spiramycin treatment is necessary, the woman should not breastfeed.
No data available.
The medicine contains less than 1 mmol (23 mg) of sodium per tablet, which means the medicine is considered "sodium-free".
Always take this medicine exactly as your doctor has told you. If you are not sure, consult your doctor.
Adults
Initial dose:6 million IU per day in 2 divided doses; this dose can be increased to
9 million IU per day, given in 3 divided doses.
In streptococcal pharyngitis and tonsillitis, treatment lasts for 10 days.
Prevention of meningococcal meningitis:3 million IU every 12 hours for 5 days.
Children
Initial dose:150,000 IU/kg body weight per day in 2-3 divided doses;
this dose can be increased to 300,000 IU/kg body weight per day, given in 2-3 divided doses.
In streptococcal pharyngitis and tonsillitis, treatment lasts for 10 days.
Prevention of meningococcal meningitis:75,000 IU/kg body weight every 12 hours for 5 days.
Swallow the tablets whole with a glass of water.
As a result of taking large doses, gastrointestinal symptoms may occur: nausea, vomiting, diarrhea.
In case of spiramycin overdose, the doctor will order an ECG, especially if the patient has risk factors for QT interval prolongation in the ECG (decreased potassium levels in the blood, congenital QT interval prolongation, taking medications that prolong the QT interval or increase the risk of ventricular arrhythmias).
There is no specific antidote effective in case of spiramycin overdose. In case of poisoning, symptomatic treatment is recommended.
In case of taking a higher dose of the medicine than recommended, consult a doctor or pharmacist immediately.
If a dose is missed, take it as soon as possible, unless it is close to the time of the next dose. Do not take two doses of the medicine at the same time or at short intervals.
In case of doubts, consult a doctor.
Do not stop treatment without consulting a doctor. Treatment should be continued for as long as the doctor recommends.
In case of further doubts about the use of this medicine, consult a doctor.
Like all medicines, Rovamycine can cause side effects, although not everybody gets them.
The following side effects may occur during treatment with the medicine.
Common side effects (may occur in up to 1 in 10 patients):
Side effects with unknown frequency (cannot be estimated from available data):
If you experience any side effects, including any side effects not listed in this leaflet, tell your doctor or pharmacist.
Side effects can be reported directly to the Department of Drug Safety Monitoring of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products:
Al. Jerozolimskie 181C, 02 222 Warsaw
tel.: + 48 22 49 21 301
fax: + 48 22 49 21 309
website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder or its representative in Poland.
Reporting side effects will help gather more information on the safety of the medicine.
Store in a temperature below 25°C.
Keep the medicine out of sight and reach of children.
Do not use this medicine after the expiry date stated on the packaging after EXP.
The expiry date refers to the last day of the month.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
Rovamycine, 1.5 million IU: white or cream-white, biconvex, round tablet with the inscription RPR 107 on one side.
Rovamycine, 3 million IU: white or cream-white, biconvex, round tablet with the inscription ROVA 3 on one side.
Rovamycine, 1.5 million IU: the pack contains 16 coated tablets.
Rovamycine, 3 million IU: the pack contains 10 coated tablets.
The Simple Pharma Company Limited
Ground Floor, 71 Lower Baggot Street,
Dublin, D02 P593, Ireland
Sanofi S.r.l.
Strada Statale 17, Km 22
67019 Scoppito (AQ)
Italy
Date of last revision of the leaflet:
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.